Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.

European journal of cancer (Oxford, England : 1990) - 1 Nov 2021

Steeb Theresa, Wessely Anja, Petzold Anne, Kohl Christoph, Erdmann Michael, Berking Carola, Heppt Markus V

Abstract excerpt

BACKGROUND: Activating genomic alterations of the receptor tyrosine kinase KIT are found preferentially in certain melanoma subtypes such as acral and mucosal melanoma or melanoma arising in chronically sun-damaged skin. However, the therapeutic value of c-Kit inhibitors for these subtypes currently remains unclear. OBJECTIVES: The objective of this study was to summarise the efficacy and safety of c-Kit...

Topics

Join the communities discussing this publication.

Dasatinib
Imatinib Mesylate
Mucous Membrane
Progression-Free Survival
Proto-Oncogene Proteins c-kit

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34562816
DOI: 10.1016/j.ejca.2021.08.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.PMID 34562816Read ↗

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.Semantic proximity Read ↗

KIT and Melanoma: Biological Insights and Clinical Implications.Semantic proximity Read ↗

KIT as a therapeutic target in metastatic melanoma.Semantic proximity Read ↗

The clinical significance of KIT mutations in melanoma: a meta-analysis.Semantic proximity Read ↗

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).Semantic proximity Read ↗

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.Semantic proximity Read ↗

Sunitinib therapy for melanoma patients with KIT mutations.Semantic proximity Read ↗

Distribution and clinical role of KIT gene mutations in melanoma according to subtype: a study of 492 Spanish patients.Semantic proximity Read ↗

Functional and sensitivity profiling of the <i>KIT</i> Mutation Landscape in MelanomaSemantic proximity Read ↗

BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival.Semantic proximity Read ↗

Another Option in Our KIT of Effective Therapies for Advanced MelanomaSemantic proximity Read ↗

Treatment of acral and mucosal melanoma: Current and emerging targeted therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.